B7 33 – 6MG per vial

R 850,00 Excl. VAT

Reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, and the kidneys. Aids Sperm motility, testicular descent, joint health, preeclampsia, wound healing

Category: Tags: , , Product ID: 148

Description

Clinical Test Expectation – B7 33 – Human Subjects : Reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, and the kidneys. Aids Sperm motility, testicular descent, joint health, preeclampsia, wound healing
Strength – 6MG per vial

Introduction
This peptide exibits potent anti-fibrotic effects. It is under active research and investigation as a means of reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, kidney and more. In animal studies, B7-33 has reduced fibrosis by roughly 50%, leading to prolonged survival following injury and offering the first new means of treating heart failure in 20 years. It has been shown to reduce excessive scar formation following cardiac injury. It has also shown promise in the treatment of certain vascular disorders as well as preeclampsia of pregnancy.

Due to its unique structure, even though B7-33 binds to the RXFP1 receptor with greater affinity than the native H2-relaxin protein, B7-33 preferentially activates the pERK pathway over the cAMP pathway. The pERK pathway is known to play an important role in cell cycle arrest in the G1 phase and has been implicated in a number of diseases including protein-misfolding conditions like Alzheimer’s disease and Crutzfeld-Jacob disease. By arresting cell cycle progression in cells with RXFP1 receptors, B7-33 can produce a number of effects. It appears that its anti-fibrotic effects, however, are most likely mediated through the ability to stimulate RXFP1-angiotensin II type 2 receptor heterodimering, which activates pERK1/2 signaling and, eventually, leads to increased production of the collagen-degrading enzyme matrix metalloproteinase (MMP) -2. It is important that B7-33 promotes only pERK pathway activation as it is thought that cAMP activation may be responsible for some of the tumor-promoting effects seen with full-sequence H2-relaxin and not seen with B7-33

Dosing Details
You inject 2ml water into the vial of B7-33 from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 0.25 – 0.3 on the syringe each morning before breakfast and inject it into the tummy under the skin into the fatty skin layer.

How long will a vial last ?
A vial should last 7-8 days.

Additional information

Weight 1 g
Dimensions 4 × 1,5 × 4 cm

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.